Ginkgo Bioworks Holdings (DNA)vsVertex Pharmaceuticals Inc (VRTX)
DNA
Ginkgo Bioworks Holdings
$7.36
+2.65%
HEALTHCARE · Cap: $415.51M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 6953% more annual revenue ($12.00B vs $170.16M). VRTX leads profitability with a 32.9% profit margin vs -1.8%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
DNA
Avoid33
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DNA.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -51.1% — below average capital efficiency
Revenue declined 23.8%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
DNA profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.59 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 33/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a pioneering leader in the synthetic biology sector, utilizing advanced genetic engineering technologies to create customized bioengineered organisms for applications in pharmaceuticals, agriculture, and industrial biotech. Its proprietary platform significantly enhances cellular design for manufacturing, streamlining product development and production processes. Dedicated to addressing global challenges such as climate change and food security, Ginkgo is strategically positioned to influence a wide array of industries while driving sustainable innovation. With its commitment to bio-based solutions, the company is poised for robust growth in a rapidly evolving biotech landscape.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?